Cocrystal Pharma (NASDAQ:COCP – Get Free Report) and CytomX Therapeutics (NASDAQ:CTMX – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.
Analyst Ratings
This is a summary of recent recommendations and price targets for Cocrystal Pharma and CytomX Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cocrystal Pharma | 1 | 0 | 1 | 0 | 2.00 |
| CytomX Therapeutics | 0 | 1 | 6 | 0 | 2.86 |
Cocrystal Pharma presently has a consensus price target of $6.00, indicating a potential upside of 532.44%. CytomX Therapeutics has a consensus price target of $6.67, indicating a potential upside of 60.26%. Given Cocrystal Pharma’s higher possible upside, equities analysts clearly believe Cocrystal Pharma is more favorable than CytomX Therapeutics.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cocrystal Pharma | N/A | N/A | -$17.50 million | ($0.94) | -1.01 |
| CytomX Therapeutics | $113.63 million | 6.20 | $31.87 million | $0.40 | 10.40 |
CytomX Therapeutics has higher revenue and earnings than Cocrystal Pharma. Cocrystal Pharma is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
6.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 28.1% of Cocrystal Pharma shares are owned by company insiders. Comparatively, 6.6% of CytomX Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Volatility & Risk
Cocrystal Pharma has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 2.37, indicating that its share price is 137% more volatile than the S&P 500.
Profitability
This table compares Cocrystal Pharma and CytomX Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cocrystal Pharma | N/A | -129.69% | -89.82% |
| CytomX Therapeutics | 24.66% | 44.49% | 20.29% |
Summary
CytomX Therapeutics beats Cocrystal Pharma on 11 of the 13 factors compared between the two stocks.
About Cocrystal Pharma
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.
About CytomX Therapeutics
CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
